NCT06266975View on ClinicalTrials.gov

Chronic Kidney Disease Patient in Chronic Myloied Leukemia

Not yet recruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Chronic Myeloid Leukemia in Remission
Interventions
DEVICE

Biobsy from kidney

using tyrosine kinase inhibitors particulary imatinib in ttt CML patients

All Listed Sponsors
lead

Sahar Mohammed Gad

OTHER

NCT06266975 - Chronic Kidney Disease Patient in Chronic Myloied Leukemia | Biotech Hunter | Biotech Hunter